Chiara Garonzi

Dr. Chiara Garonzi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
CGChiara Garonzi
Chiara Garonzi
GFGun Forsander
Gun Forsander
CMClaudio Maffeis
Claudio Maffeis
Nutrition therapy is a cornerstone of type 1 diabetes (T1D) management. Glycemic control is affected by diet composition, which can contribute to the development of diabetes complications. However, the specific role of macronutrients is still debated, particularly fat intake. This review aims at assessing the relationship between fat intake and glycemic control, cardiovascular risk factors, inflammation, and microbiota, in children and adolescents with T1D. High fat meals are followed by delayed and prolonged hyperglycemia and higher glycated hemoglobin A1c levels have been frequently reported in individuals with T1D consuming high amounts of fat. High fat intake has also been associated with increased cardiovascular risk, which is higher in people with diabetes than in healthy subjects. Finally, high fat meals lead to postprandial pro-inflammatory responses through different mechanisms, including gut microbiota modifications. Different fatty acids were proposed to have a specific role in metabolic regulation, however, further investigation is still necessary. In conclusion, available evidence suggests that a high fat intake should be avoided by children and adolescents with T1D, who should be encouraged to adhere to a healthy and balanced diet, as suggested by ISPAD and ADA recommendations. This nutritional choice might be beneficial for reducing cardiovascular risk and inflammation.

12 December 2022 in Hormone Research in Paediatrics
Verified
Journal Article
Open access
PDF file
CGChiara Garonzi
Chiara Garonzi
Alice MaguoloAlice Maguolo
Alice Maguolo
CMClaudio Maffeis
Claudio Maffeis
It is still a matter of debate which is the most suitable diagnostic test for risk-based screening of prediabetes and type 2 diabetes (T2D) in children and adolescents with overweight or obesity. This review highlighted benefits and pitfalls of currently recommended screening tools (fasting plasma glucose [FPG], oral glucose tolerance test [OGTT], glycated hemoglobin A1c [HbA1c]). The greatest advantage of OGTT is the ability to detect people with impaired glucose tolerance, a subcategory at high risk of developing both T2D and cardiovascular disease. Important disadvantages are low reproducibility and inconvenience. FPG measurement is more practical, as it needs only one blood draw, although both OGTT and FPG require fasting. The reliability of HbA1c as a screening tool has been questioned, especially in children and adolescents, but its undeniable convenience can lead to increased adherence to screening. In contrast, it can be altered by several nonglycemic factors. Importantly, none of these tests have been validated in the pediatric population. Alternative tests have been recently proposed, including new OGTT-derived biomarkers and additional nonfasting glycemic markers. In conclusion, when choosing the most suitable test in clinical practice, advantages and disadvantages should be considered, as well as the possibility of performing different tests at once.

23 March 2021 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
CGChiara Garonzi
Chiara Garonzi
MCMatteo Chinello
Matteo Chinello
Simone CesaroSimone Cesaro
Simone Cesaro
Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening hyperinflammatory syndrome. Standard treatment is based on immunosuppressive, cytotoxic drugs and hematopoietic stem cell transpl...

5 March 2021 in Hematology Reports
Verified
Journal Article
Open access
PDF file
LDLara Devilli
Lara Devilli
CGChiara Garonzi
Chiara Garonzi
RBRita Balter
Rita Balter
EBElisa Bonetti
Elisa Bonetti
MCMatteo Chinello
Matteo Chinello
Simone CesaroSimone Cesaro
Simone Cesaro
Long-term survival for acute lymphoblastic leukemia (ALL) in children improved over the last three decades up to 80–90% of affected patients. Consequently, the quality of life of survivors has become increasingly important. This study analyses the clinical features and outcome of 119 children with ALL, focusing on the quality of long-term survival in a subset of 22 patients over 18 years of age. Among this group, the 10-year event-free survival and overall survival were 83.1% (C.I. 74.0–89.2) and 88.4% (C.I. 80.9–93.1), respectively. Treatment related long-term medical complications were reported only in 2 patients (9.1%). Secondary school was completed successfully in 20 of 22 patients (89.9%). The remaining 2 patients were still attending at the time of the analysis. In conclusion, current treatment for ALL is well tolerated and does not compromise significantly the quality of life of survivors.

1 January 2020 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
CGChiara Garonzi
Chiara Garonzi
RBRita Balter
Rita Balter
GTGloria Tridello
Gloria Tridello
APAnna Pegoraro
Anna Pegoraro
MPManuela Pegoraro
Manuela Pegoraro
Simone CesaroSimone Cesaro
Simone Cesaro
BACKGROUND, OBJECTIVES The antibody titer of vaccine-preventable disease in 70 patients who underwent chemotherapy or haemopoietic stem cell transplantation (HSCT) was assessed in order to evaluate the seroprotection after treatment and the feasibility and the efficacy of a policy of revaccination. METHODS Serum antibody titers of 70 patients for hepatitis B (HBV), Rubella, Varicella-zoster (VZV), Measles, Mumps, Polio viruses, Clostridium tetani (C. tetani) and Streptococcus pneumoniae (S. Pneumoniae) were analysed. RESULTS After chemotherapy, a lack of protective antibody titers against HBV, Rubella, VZV, Measles, Mumps, Polio viruses, C. tetani and S. Pneumoniae were found in 53%, 45%, 46%, 46%, 43%, 21-26%, 88% and 55% of patients, respectively. In patients who were tested both before and after chemotherapy, the loss of immunity was respectively 39%, 43%, 38%, 42%, 32%, 33%, and 80%. A low number of B-lymphocytes was associated with the loss of immunity against Measles (p=0.04) whereas a high number of CD8+ T-lymphocytes was associated with the loss of immunity against VZV (p=0.03). A single booster of vaccine dose resulted in a seroprotection for HBV, Rubella, VZV, Measles, Mumps, Polio viruses, C. tetani and S. Pneumoniae in 67%, 83%, 80%, 67%, 33%, 100%, 88% and 67% of patients, respectively. After HSCT, the rates of lack and loss of vaccine immunity differ by the infectious disease considered. CONCLUSIONS We confirm that seroprotection for vaccine-preventable disease is affected by treatment for pediatric malignancy. A single booster dose of vaccine might be a practical way to restore vaccine immunity in patients after chemotherapy.

11 April 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
CGChiara Garonzi
Chiara Garonzi
FZFrancesca Zeni
Francesca Zeni
GTGloria Tridello
Gloria Tridello
AGAlice Giacomazzi
Alice Giacomazzi
ACAlberto Castagna
Alberto Castagna
Simone CesaroSimone Cesaro
Simone Cesaro
Background: Central venous catheter (CVC)‐related complications remain a significant cause of morbidity in pediatric hematology‐oncology. We prospectively surveyed the incidence of CVC‐related complications in children with hematologic‐oncologic diseases. Procedure: Five‐hundred‐eighty‐one CVCs were inserted in 421 patients from January 2010 to June 2022 (153,731 CVC days observation; follow‐up data up to December 31, 2022). Results: Overall, 671 complications were recorded (4.365/1000 CVC days): 49.7% malfunctions (1.88/1000 CVC days, 4.8% of CVC early removals), 23.9% bacteremia (0.90/1000, 15.1%), 19.6% mechanical complications (0.74/1000, 70.2%), 20.1% localized infections (0.76/1000, 17.1%), 0.5% thrombosis (0.02/1000, 33.3%). At multivariate analysis, risk factors for malfunction were Broviac–Hickman type of CVC (hazard ratio [HR] 2.5) or Port‐a‐cath (HR 3.4) or Proline (HR 4.3), p < .0001; for bacteremia double‐lumen CVC (HR 3.2, p < .0001); for mechanical complications age at CVC insertion under median (HR 4.5, p < .0001) and Broviac–Hickman (HR 1.6) or Proline (HR 2.7), p = .01; finally for localized infections Broviac–Hickman (HR 2.9) or Proline (HR 4.4), p = .0001. The 2‐year cumulative incidence of premature removal was 23.5%, and risk factors were age at CVC insertion under median (HR 2.4, p < .0001), Broviac–Hickman (HR 2.3) or Proline (HR 4.2), p < .0001. Conclusions: Premature removal occurs in approximately 20%–25% of long‐term CVCs. A surveillance program has a fundamental role in identifying the risk factors for CVC complications and the areas of intervention to improve CVC management.